Beta
Dalteparin
medication Under reviewA low-molecular-weight heparin used to prevent and treat blood clots.
Research summary
Human clinical research on dalteparin is extensive, but it overwhelmingly focuses on patients with specific medical conditions such as acute medical illness, critical illness in intensive care units, cancer-associated thrombosis, or those undergoing surgery or hemodialysis. Large randomized controlled trials and comparative studies show that dalteparin reduces the incidence of venous thromboembolism compared with placebo or provides similar or improved efficacy compared with unfractionated heparin, generally with a low but real risk of major bleeding. There is essentially no evidence base in healthy, free-living adults without medical indications that would justify its use as a general wellness or performance-enhancing supplement. In healthy volunteers and low-risk surgical patients where data exist, dalteparin behaves as an effective anticoagulant with safety dependent on dose and clinical context, but the risk of bleeding and other adverse effects means it is not appropriate for routine use outside physician-supervised therapy. The research consensus is that dalteparin is a specialized anticoagulant medication, not a general health supplement.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Dalteparin to your stack to report effects
Safety of dalteparin prophylaxis against deep venous thrombosis in orthopedic oncology patients
Lin P, et al.
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients
Leizorovicz A, Cohen AT, Turpie AGG, et al.
Prophylaxis for Thromboembolism in Critical Care (PROTECT) Trial: Dalteparin versus unfractionated heparin in critically ill patients
Arnold DM, Lauzier F, Meade MO, et al.
No reports yet
Be the first to report this effect and help the community.
Add Dalteparin to your stack to report effects
Safety of dalteparin prophylaxis against deep venous thrombosis in orthopedic oncology patients
Lin P, et al.
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients
Leizorovicz A, Cohen AT, Turpie AGG, et al.
Prophylaxis for Thromboembolism in Critical Care (PROTECT) Trial: Dalteparin versus unfractionated heparin in critically ill patients
Arnold DM, Lauzier F, Meade MO, et al.
No side effects tracked yet
No side effects have been reported by studies or users for this habit yet.
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Coronary artery disease or other cardiac conditions
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients
Leizorovicz A, Cohen AT, Turpie AGG, et al.
Research (3 studies)
Prophylaxis for Thromboembolism in Critical Care (PROTECT) Trial: Dalteparin versus unfractionated heparin in critically ill patients
Arnold DM, Lauzier F, Meade MO, et al.
Safety of dalteparin prophylaxis against deep venous thrombosis in orthopedic oncology patients
Lin P, et al.
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients
Leizorovicz A, Cohen AT, Turpie AGG, et al.
Community updates
No updates yet for this supplement.
Be the first to share your experience!